(Q79174651)

English

Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)

scientific article published on 01 October 2006

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17015809

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17015809%20AND%20SRC:MED&resulttype=core&format=json

retrieved

20 December 2019

title

Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17015809

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17015809%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

1

Robert A Rosenheck

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17015809

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17015809%20AND%20SRC:MED&resulttype=core&format=json

retrieved

20 December 2019

publication date

1 October 2006

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17015809

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17015809%20AND%20SRC:MED&resulttype=core&format=json

retrieved

20 December 2019

number of pages

3

1 reference

based on heuristic

inferred from page(s)

published in

JAMA Psychiatry

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17015809

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17015809%20AND%20SRC:MED&resulttype=core&format=json

retrieved

20 December 2019

volume

63

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17015809

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17015809%20AND%20SRC:MED&resulttype=core&format=json

retrieved

20 December 2019

issue

10

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17015809

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17015809%20AND%20SRC:MED&resulttype=core&format=json

retrieved

20 December 2019

page(s)

1074-1076

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17015809

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17015809%20AND%20SRC:MED&resulttype=core&format=json

retrieved

20 December 2019

Identifiers

DOI

10.1001/ARCHPSYC.63.10.1074

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17015809

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17015809%20AND%20SRC:MED&resulttype=core&format=json

retrieved

20 December 2019

PubMed publication ID

17015809

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17015809

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17015809%20AND%20SRC:MED&resulttype=core&format=json

(Q79174651)

Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)